PMD Healthcare touted data today from a pediatric cystic fibrosis study which the company said demonstrates the feasibility of at-home spirometry using its Spiro PD device.
Cystic fibrosis patients take a variety of medications daily, PMD pointed out, and adherence to complicated regimens can be a challenge.
The Allentown, Penn.-based company’s study examined forced expiratory volume, body mass index and treatment burden scores of the intervention group compared to the control group.
Nearly 78% of patients surveyed in the study supported frequent monitoring of pulmonary function and 29 out of the 40 patients endorsed the use of at-home spirometry as an adherence intervention, PMD reported. Almost 95% of patients were adherent to the Spiro PD device.
Medication reminders from the company’s Spiro PD device were identified as an adherence motivator, according to PMD. Overall, pulmonary function tests, body mass index and treatment burden scores improved in the intervention group compared to the control group.
“This study offers further evidence of how remote patient monitoring and supportive adherence reminders, can have a positive impact on patient self- management and play a pivotal role in treatment success,” executive VP Steve Sullivan said in prepared remarks.
Spiro PD, which PMD touts as the 1st personal spirometer, won FDA approval in 2011. The company said it is launching the 2nd-generation device, Spiro PD 2.0, and its Wellness Management System to connect patients and caregivers using telemonitoring technology.
